by Rod D. Martin
August 12, 2013
Our liver fibrosis drug has received Fast Track designation from the federal Food and Drug Administration. This is a very big deal, for Galectin Therapeutics (NASDAQ:GALT) — part of the 10 X Fund and Martin Organization portfolio — but also for millions of people with no treatment and no hope. Liver fibrosis can only be “treated” by a transplant, and while roughly 6,000 people will get a transplant each year, the disease affects millions.
Brief coverage in today’s Wall Street Journal here. You’ll be hearing more: we’re just getting started.